Welcome to
BGI Australia

A Memorandum of Understanding (MOU) between BGI and Xing Technologies is signed on 22 Aug 2018 supporting collaborative research and product innovation in the following areas: 

• DNB technology: optimise current DNA nanoball technology to improve sequencing data quality and throughput resulting in reduced sequencing costs;
• Circulating Tumour/Stem Cells (CTC) technology (cells shed from a primary tumour that disseminate in the body’s circulatory system): integrate CTC isolation, characterisation and sequencing for fast and accurate disease screening and monitoring;
• Point-of-care product: based on XING’s patented “Laboratory in a Drop” technology, undertake joint research into, and manufacturing of, a transformative diagnostic product developed by XING to offer the world, including millions of Australians, an accurate, rapid and inexpensive point-of-care disease screening, diagnosis & monitoring kit, which will revolutionise current practice. The applications even extend to human health as well as animals and plant material, such as agriculture, aquaculture, veterinary science.

MGI is pleased to announce the appointment of Decode Science as the distributor for the MGI range of next generation sequencers and related products in Australia and New Zealand regions. This partnership levers the strengths of both organisations to provide strong local support for customers. In true partnership the MGI Australia team and Decode Science will jointly provide after sales applications and service support to new and existing units in the market. The key contact details for Decode Science are listed below:

Decode Science Pty Ltd 

ABN:  24 615 709 245 

Add.: Eastern Innovation Centre, 5a Hartnett Place, Mulgrave 3170

Email:  sales@decodescience.com.au

Phone: 1800 724 3625

Contact:  Joshua Warburton

About Decode Science

Decode Science is a privately owned Australian organisation specialising in the Life Science market.  Founded in 2016 Decode Science has rapidly grown to provide national coverage of Australia and New Zealand.  Decode Science has a vision to enable discovery amongst the scientific community by providing the best products from around the globe aligned with best-in-class local support.

Integrating genomics and artificial intelligence to predict treatment responses in cancer patients is going to become a reality. A major collaborative research project “Artificial Intelligence and Genomics to Predict Cancer Treatment” has been awarded a $2.6 million CRC-P Grant (Cooperative Research Centre Projects) by Australian Government. The official announcement is made today by Assistant Minster for Science, Jobs and Innovation, Zed Seselja, and Federal Member for Brisbane, Trevor Evans on 25 Jul 2018. 

BGI is the Next-Gen Sequencing partner of the Project, in collaboration with other world leading partners including Max Kelsen the leading partner specialised in artificial intelligence technology, QIMR Berghofer Medical Research Institute as the research partner, Queensland Health Metro North Hospital and Health Service as the clinical partner, and genomiQa as the bioinformatic analysis partner.

The Project will receive $2.6 million under the fifth round of the CRC-P Program, and has attracted $6.4 million of cash and in-kind contributions from industry partners. "This project will firmly establish the role of artificial intelligence and whole genome analysis in the future of precision medicine" said Nicholas Therkelsen-Terry CEO of Max Kelsen.

Colin Albert, CEO of genomiQa, a spin-out company of QIMR Berghofer Institute of Medical Research said the project would help to unlock the value of whole genome data for patients and clinicians. “This project will firmly establish the role of whole genome analysis and artificial intelligence to help predict the response of immunotherapy for the treatment of cancer.” 

Mr Albert said genomiQa’s high-quality genomic pipeline was developed by founders Dr Nic Waddell and Dr. John Pearson.

Dr. Bicheng Yang, Director of BGI Australia said, “BGI is proud to provide sequencing support for this $9.1 million project, which will help establish whole genome sequencing as part of routine clinical practice, as BGI’s objective is to make sequencing more affordable and accessible to benefit the general public”.  More in the News

MGI, the manufacturing subsidiary under BGI Group, has received China Food and Drug Administration (CFDA) certification for its latest two models of next generation genetic sequencers. MGISEQ-2000 and MGISEQ-200 sequencers have been granted the Medical Device Registration Certificate (MDRC) by CFDA on 25th June 2018. MGI is the first organisation in China to receive the certification from CFDA for next-generation sequencing diagnostic products and medical devices. These two new sequencers will not just play an important role in scientific rsearch, but also contribute to a wide range of applications in the clinical medicine industry. Healthcare organisations will now have the confidence using the world’s leading sequencing solution to perform whole genome sequencing (WGS). MGISEQ-2000 supports two different types of Flow Cells and provides an independent dual Flow Cell operating platform. Users can combine dozens of different operating modes to provide more diversified options for sequencing. It can produce 1080G of high-quality sequencing data, and in PE100 mode at a full load MGI-2000 can provide single end-to-end sequencing within 48 hours. MGISEQ-200 is an instrument of convenience and flexibility. It takes less than 48 hours to produce 60G of high-quality sequencing data while functioning in PE100 mode at a full load. MGISEQ-200 can complete rapid tests of 24 tumor samples in one day.